Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
Q4 2024 vs. Q3 2024
How the institutions holding Gain Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 19 | 25 | +6 |
| Shares | 1.68M | 1.98M | +308.5K (+18.4%) |
| Value | $2.40M | $3.94M | +$1.55M (+64.5%) |
New holders (10)
Institutions that held Gain Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 91,738 | $198.2K | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 54,500 | $118.0K | 0.00% |
| Susquehanna International Group, LLP | 46,913 | $101.3K | 0.00% |
| Bridgeway Capital Management, LLC | 30,004 | $64.8K | 0.00% |
| Royal Bank of Canada | 17,500 | $38.0K | 0.00% |
| Benedict Financial Advisors Inc | 16,000 | $34.6K | 0.01% |
| Sprott Inc. | 14,000 | $30.2K | 0.00% |
| Citadel Advisors LLC | 11,612 | $25.1K | 0.00% |
| MAI Capital Management | 4,410 | $9.53K | 0.00% |
| Citigroup Inc | 2,000 | $4.32K | 0.00% |
Sold out (4)
Institutions that held Gain Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Renaissance Technologies LLC | 53,264 | $94.8K |
| Tower Research Capital LLC (TRC) | 4,842 | $8.62K |
| Simplex Trading, LLC | 4,801 | $8.00K |
| Group One Trading, L.P. | 1,401 | $2.49K |